Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

ABRAHAM S SALACATA

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1255440095
CMS profile
101995
Location
ALPENA, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$1,254.35

23 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Travel and Lodging $796.85 6
Food and Beverage $457.50 17

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

ABRAHAM S SALACATA

NPI 1255440095 · CMS profile ID 101995

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

ALPENA, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255440095?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
ABRAHAM S SALACATA, NPI 1255440095, CMS profile ID 101995. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255440095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). ABRAHAM S SALACATA, NPI 1255440095, CMS profile ID 101995. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255440095?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
ABRAHAM S SALACATA, NPI 1255440095, CMS profile ID 101995, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–23 of 23 matching records. This page contains 23 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1255440095?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

23 matching records · $1,254.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 23 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–23 of 23.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
PFIZER INC. $10.9112/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673729261 CMS
AstraZeneca Pharmaceuticals LP $14.2807/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685534197 CMS
Boston Scientific Corporation $139.7506/07/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059107 CMS
Boston Scientific Corporation $38.2506/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059075 CMS
Boston Scientific Corporation $38.2506/06/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059080 CMS
Boston Scientific Corporation $65.0006/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059093 CMS
Boston Scientific Corporation $96.4106/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059103 CMS
Boston Scientific Corporation $48.1506/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059087 CMS
Boston Scientific Corporation $65.6406/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059097 CMS
Boston Scientific Corporation $152.2706/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059111 CMS
Boston Scientific Corporation $380.1806/05/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059119 CMS
Boston Scientific Corporation $10.4005/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059057 CMS
W. L. Gore & Associates, Inc. $41.6705/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705047971 CMS
Novartis Pharmaceuticals Corporation $11.5904/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659956133 CMS
Janssen Pharmaceuticals, Inc $12.1404/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659257385 CMS
AstraZeneca Pharmaceuticals LP $12.9904/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 685350325 CMS
Boston Scientific Corporation $16.4504/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059069 CMS
E.R. Squibb & Sons, L.L.C. $11.2002/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 651444637 CMS
Novartis Pharmaceuticals Corporation $12.1202/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659956127 CMS
Boston Scientific Corporation $39.6302/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059083 CMS
Boston Scientific Corporation $14.9101/24/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059063 CMS
Janssen Pharmaceuticals, Inc $13.4801/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659257383 CMS
Boston Scientific Corporation $8.6801/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 663059053 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,254.35 23
PY2020 $1,854.77 27
PY2021 $993.92 38
PY2022 $880.13 46
PY2023 $854.49 36
PY2024 $347.73 18
PY2025 $2,156.96 21

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2021 Principal investigator $34,407.43 44
PY2020 Principal investigator $48,633.68 82
PY2019 Principal investigator $95,505.89 140

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

140 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Amgen Inc. $570.00 12/24/2019 Non-covered Recipient Entity
ENDEAVOR MEDICAL RESEARCH
GOULD No dispute reported 06/30/2026 675778109
Principal investigator 1 Boehringer Ingelheim International GmbH $858.00 12/13/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703927729
Principal investigator 1 Boehringer Ingelheim International GmbH $858.00 12/13/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703927731
Principal investigator 1 Boehringer Ingelheim International GmbH $858.00 12/03/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703924665
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $508.29 11/30/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 704738009
Principal investigator 1 Boehringer Ingelheim International GmbH $956.00 11/18/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703923123
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 11/18/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703923737
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 11/18/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703923741
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 11/18/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703923833
Principal investigator 1 Boehringer Ingelheim International GmbH $693.00 11/18/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703923843
Principal investigator 1 Boehringer Ingelheim International GmbH $796.00 11/18/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703923991
Principal investigator 1 Boehringer Ingelheim International GmbH $796.00 11/18/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703923999
Principal investigator 1 Boehringer Ingelheim International GmbH $82.82 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924887
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924893
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924897
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924927
Principal investigator 1 Boehringer Ingelheim International GmbH $31.06 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924929
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924933
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924943
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924949
Principal investigator 1 Boehringer Ingelheim International GmbH $23.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924977
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924983
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703924987
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703925025
Principal investigator 1 Boehringer Ingelheim International GmbH $26.59 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925027
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925031
Principal investigator 1 Boehringer Ingelheim International GmbH $26.56 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925037
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925039
Principal investigator 1 Boehringer Ingelheim International GmbH $0.22 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925043
Principal investigator 1 Boehringer Ingelheim International GmbH $20.70 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703925045
Principal investigator 1 Boehringer Ingelheim International GmbH $41.41 11/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703927097
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,574.60 10/31/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 704738007
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 09/10/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918443
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $508.29 08/31/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704738005
Principal investigator 1 Boehringer Ingelheim International GmbH $858.00 08/06/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703917919
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 08/05/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703916243
Principal investigator 1 Boehringer Ingelheim International GmbH $796.00 08/05/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703917169
Principal investigator 1 Boehringer Ingelheim International GmbH $858.00 08/05/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703917749
Principal investigator 1 Boehringer Ingelheim International GmbH $10.27 08/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703919993
Principal investigator 1 Boehringer Ingelheim International GmbH $10.27 08/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703920093
Principal investigator 1 Boehringer Ingelheim International GmbH $10.27 08/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703920099
Principal investigator 1 Boehringer Ingelheim International GmbH $20.54 08/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703920101
Principal investigator 1 Boehringer Ingelheim International GmbH $10.27 08/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703920103
Principal investigator 1 Boehringer Ingelheim International GmbH $38.75 08/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703920193
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 08/01/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703916523
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 08/01/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703917297
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 08/01/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703917515
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $3,049.73 07/31/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704738003
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 07/08/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703915425
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 07/08/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703915427
Principal investigator 1 Boehringer Ingelheim International GmbH $693.00 07/08/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703915429
Principal investigator 1 Boehringer Ingelheim International GmbH $336.00 07/08/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703915431
Principal investigator 1 Boehringer Ingelheim International GmbH $41.85 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918639
Principal investigator 1 Boehringer Ingelheim International GmbH $62.78 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918641
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918645
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918647
Principal investigator 1 Boehringer Ingelheim International GmbH $10.46 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918649
Principal investigator 1 Boehringer Ingelheim International GmbH $99.42 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918677
Principal investigator 1 Boehringer Ingelheim International GmbH $26.11 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918679
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918681
Principal investigator 1 Boehringer Ingelheim International GmbH $10.46 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918683
Principal investigator 1 Boehringer Ingelheim International GmbH $10.46 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918687
Principal investigator 1 Boehringer Ingelheim International GmbH $23.95 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703918689
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918691
Principal investigator 1 Boehringer Ingelheim International GmbH $31.39 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918693
Principal investigator 1 Boehringer Ingelheim International GmbH $31.39 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918695
Principal investigator 1 Boehringer Ingelheim International GmbH $41.85 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918697
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918699
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918727
Principal investigator 1 Boehringer Ingelheim International GmbH $26.87 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918729
Principal investigator 1 Boehringer Ingelheim International GmbH $20.93 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918731
Principal investigator 1 Boehringer Ingelheim International GmbH $49.71 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918733
Principal investigator 1 Boehringer Ingelheim International GmbH $26.11 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703918735
Principal investigator 1 Boehringer Ingelheim International GmbH $10.46 07/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703926577
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,541.44 06/30/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704737993
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,541.44 06/30/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704737995
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,541.44 06/30/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704737997
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,541.44 06/30/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704737999
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,541.44 06/30/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704738001
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $321.64 06/21/2019 Non-covered Recipient Entity
Midmichigan Cardiology
An Open-label, 2 x 2 Factorial, Randomized Controlled, Clinical Trial to Evaluate the Safety of Apixaban vs. Vitamin K Antagonist and Aspirin vs. Aspirin Placebo in Patients with Atrial Fibrillation and Acute Coronary Syndrome or Percutaneous Coronary Int No dispute reported 06/30/2026 639759989
Principal investigator 1 Boehringer Ingelheim International GmbH $956.00 06/12/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703912697
Principal investigator 1 Boehringer Ingelheim International GmbH $336.00 06/12/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703912943
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 06/12/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703912945
Principal investigator 1 Boehringer Ingelheim International GmbH $724.00 05/17/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703911661
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 05/17/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703911721
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 05/17/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703911827
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 05/17/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703911829
Principal investigator 1 Boehringer Ingelheim International GmbH $1,090.00 05/17/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703926107
Principal investigator 1 Boehringer Ingelheim International GmbH $1,006.00 05/17/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703926171
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,100.00 05/03/2019 Non-covered Recipient Entity
Endeavor Medical Research
BAY59-7939 prevention of CV events in vascular disease No dispute reported 06/30/2026 629168397
Principal investigator 1 Boehringer Ingelheim International GmbH $724.00 05/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703912281
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 04/10/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703911247
Principal investigator 1 Boehringer Ingelheim International GmbH $51.94 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703913863
Principal investigator 1 Boehringer Ingelheim International GmbH $20.78 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703913869
Principal investigator 1 Boehringer Ingelheim International GmbH $41.55 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703913871
Principal investigator 1 Boehringer Ingelheim International GmbH $39.20 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703913951
Principal investigator 1 Boehringer Ingelheim International GmbH $31.16 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703913953
Principal investigator 1 Boehringer Ingelheim International GmbH $62.33 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703913959
Principal investigator 1 Boehringer Ingelheim International GmbH $31.16 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703913963
Principal investigator 1 Boehringer Ingelheim International GmbH $20.78 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703913965
Principal investigator 1 Boehringer Ingelheim International GmbH $31.16 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703913967
Principal investigator 1 Boehringer Ingelheim International GmbH $53.29 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914043
Principal investigator 1 Boehringer Ingelheim International GmbH $31.16 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914045
Principal investigator 1 Boehringer Ingelheim International GmbH $20.78 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914047
Principal investigator 1 Boehringer Ingelheim International GmbH $20.78 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914049
Principal investigator 1 Boehringer Ingelheim International GmbH $20.78 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914051
Principal investigator 1 Boehringer Ingelheim International GmbH $62.33 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914053
Principal investigator 1 Boehringer Ingelheim International GmbH $20.78 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914055
Principal investigator 1 Boehringer Ingelheim International GmbH $20.78 04/02/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703914057
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,033.16 03/31/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 704737989
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $2,541.44 03/31/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704737991
Principal investigator 1 Boehringer Ingelheim International GmbH $1,146.00 03/25/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703910847
Principal investigator 1 Boehringer Ingelheim International GmbH $950.00 03/25/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703910849
Principal investigator 1 Boehringer Ingelheim International GmbH $950.00 03/25/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703910851
Principal investigator 1 Boehringer Ingelheim International GmbH $831.00 03/22/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703925839
Principal investigator 1 Boehringer Ingelheim International GmbH $785.00 03/12/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907127
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $6,300.00 03/06/2019 Non-covered Recipient Entity
Endeavor Medical Research
BAY59-7939 prevention of CV events in vascular disease No dispute reported 06/30/2026 629168659
Principal investigator 1 AstraZeneca Pharmaceuticals LP $7,283.97 03/05/2019 Non-covered Recipient Entity
Endeavor Medical Research Center
Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes No dispute reported 06/30/2026 684980317
Principal investigator 1 Boehringer Ingelheim International GmbH $54.17 03/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703910845
Principal investigator 1 Boehringer Ingelheim International GmbH $27.09 03/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703926553
Principal investigator 1 Boehringer Ingelheim International GmbH $858.00 03/01/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907123
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 03/01/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907125
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 03/01/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703910843
Principal investigator 1 Boehringer Ingelheim Pharma GmbH & Co.KG $4,574.60 02/28/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 704738011
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 02/19/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703906705
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 02/19/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703906891
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,725.00 02/01/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
GLORIA AF Registry Phase II III Core No dispute reported 06/30/2026 704144407
Principal investigator 1 Boehringer Ingelheim International GmbH $81.00 01/22/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703904929
Principal investigator 1 Boehringer Ingelheim International GmbH $724.00 01/22/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703905827
Principal investigator 1 Amgen Inc. $9,120.00 01/10/2019 Non-covered Recipient Entity
ENDEAVOR MEDICAL RESEARCH
GOULD No dispute reported 06/30/2026 675785453
Principal investigator 1 Boehringer Ingelheim International GmbH $432.93 01/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907109
Principal investigator 1 Boehringer Ingelheim International GmbH $232.30 01/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907111
Principal investigator 1 Boehringer Ingelheim International GmbH $221.74 01/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907113
Principal investigator 1 Boehringer Ingelheim International GmbH $232.30 01/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907115
Principal investigator 1 Boehringer Ingelheim International GmbH $137.27 01/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907117
Principal investigator 1 Boehringer Ingelheim International GmbH $126.71 01/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907119
Principal investigator 1 Boehringer Ingelheim International GmbH $168.95 01/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and heart failure (HFpEF) No dispute reported 06/30/2026 703907121
Principal investigator 1 Boehringer Ingelheim International GmbH $185.94 01/04/2019 Non-covered Recipient Entity
ENDEAVOR MEDCL RSRCH
Empagliflozin and Heart failure (HFrEF) No dispute reported 06/30/2026 703910841
Principal investigator 1 Novartis Pharmaceuticals Corporation $3,157.92 01/01/2019 Non-covered Recipient Entity
ENDEAVOR MEDICAL RESEARCH
PROSPECTIVE COMPARISON OF COMBINED ANGIOTENSIN NEPRILYSIN INHIBITION WITH LCZ696 RELATIVE TO ENALAPRIL ON CENTRAL AORTIC STIFFNESS AND VENTRICULAR VASCULAR COUPLING IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION No dispute reported 06/30/2026 640715981
Principal investigator 1 Novartis Pharmaceuticals Corporation $2,085.00 01/01/2019 Non-covered Recipient Entity
ENDEAVOR MEDICAL RESEARCH
OBSERVATIONAL REGISTRY OF TREATMENT PATTERNS IN US HEART FAILURE PATIENTS WITH REDUCED EJECTION FRACTION No dispute reported 06/30/2026 640715985